BioHOBIT: The Biomarkers In The Hyperbaric Oxygen Brain Injury Treatment Trial

The Biomarkers in the Hyperbaric Oxygen Brain Injury Treatment Trial (BioHOBIT) Abstract There continues to be an overarching problem of high mortality and poor outcome for victims of severe traumatic brain injury (TBI). Preclinical and clinical investigations indicate that hyperbaric oxygen (HBO) has a positive impact on reducing brain injury and improving outcomes in severe TBI. By markedly increasing oxygen (O2) delivery to the traumatized brain, HBO can reverse the lack of O2 that precipitates cellular energy failure and subsequent brain cell death as studied in a phase 2 trial, HOBIT. The University of Kentucky Department of Anesthesiology is one site in this NIH funded multi-site trial. Running concurrently with this trial, is the Biomarkers in the Hyperbaric Oxygen Brain Injury Treatment Trial, BioHOBIT. All HOBIT sites are receiving additional funding (R011NS114251) to collect serum, plasma, buffy coat, and cerebral spinal fluid (in patients with an existing ventricular drain) to analyze biomarkers thought to play a role in brain injury under Bio-HOBIT trial funding.